59 completed, 21 terminated, 10 unknown, 5 recruiting. 55 Phase 2, 38 Phase 1, 8 Not applicable, 5 Phase 3.
Follow Hodgkin's Lymphoma: new trials by email Literature Review of Hodgkin's Lymphoma trials Research Report on Hodgkin's Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma LCAR-HL30 cells - Hodgkin's Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Recruiting | Ruijin Hospital | 32 | 2024-07-01 | 2024-07-10 |
| A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma Azacytidine, Pembrolizumab - Hodgkin's Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 24 | 2022-10-05 | 2026-05-18 |
| A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers XmAb20717 - Microsatellite High Cancers, Peritoneal Mesothelioma | Phase 2 | Suspended | M.D. Anderson Cancer Center | 140 | 2022-08-05 | 2026-10-13 |
| A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) Pembrolizumab - Hodgkin's Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Phase 2 | Completed | Merck Sharp & Dohme LLC | 66 | 2021-06-07 | 2025-10-29 |
| A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis - Hodgkin's Lymphoma | Not applicable | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 20 | 2020-10-22 | 2020-12-29 |
| Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Pembrolizumab, Umbralisib - Hodgkin's Lymphoma | Phase 2 | Terminated | University of Washington | 6 | 2019-09-26 | 2023-05-03 |
| Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT) Brentuximab Vedotin - Hodgkin's Lymphoma | Phase 2 | Unknown | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 80 | 2019-05-14 | 2020-07-21 |
| A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma AK105 - Hodgkin's Lymphoma | Phase 1 / Phase 2 | Completed | Akeso | 94 | 2018-08-13 | 2024-04-03 |
| The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD Bendamustine, Gemcitabine, Dexamethasone - Hodgkin's Lymphoma | Phase 2 | Completed | Polish Lymphoma Research Group | 115 | 2017-11-06 | 2025-01-16 |
| Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders T-allo10 - AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome) | Phase 1 | Terminated | Roncarolo, Maria Grazia, MD | 5 | 2017-08-30 | 2024-07-18 |
| A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma Nivolumab, Bendamustine Hydrochloride - Hodgkin's Lymphoma | Phase 1 / Phase 2 | Completed | St. Petersburg State Pavlov Medical University | 30 | 2017-05-27 | 2020-05-28 |
| CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) CAR T Cells - Hodgkin's Lymphoma, Non-Hodgkin Lymphoma | Phase 1 | Recruiting | Baylor College of Medicine | 60 | 2017-05-08 | 2026-10-02 |
| Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma Bortezomib, Ruxolitinib - Hodgkin's Lymphoma, Lymphoma, Non-Hodgkin | Phase 1 | Completed | University of Michigan Rogel Cancer Center | 15 | 2016-05-12 | 2021-12-20 |
| Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Tinostamustine - Hematological Malignancies, Multiple Myeloma | Phase 1 | Completed | Mundipharma Research Limited | 106 | 2016-04-14 | 2024-07-25 |
| Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma G-CSF (filgrastim), Cytosine arabinoside with G-CSF (filgrastim) - Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma | Phase 3 | Unknown | Maria Sklodowska-Curie National Research Institute of Oncology | 90 | 2016-03-01 | 2016-03-30 |
| Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation Behavioral techniques - Hodgkin's Lymphoma, Leukemia | Not applicable | Completed | University of Wisconsin, Madison | 17 | 2016-03-01 | 2019-11-15 |
| Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis mycophenolate mofetil, Sargramostim, Filgrastim - Hodgkin's Lymphoma, Lymphoid Leukemia | Phase 2 | Completed | Virginia Commonwealth University | 31 | 2015-11-04 | 2023-01-23 |
| Reduced Intensity Conditioning Transplant Using Haploidentical Donors Fludarabine, Melphalan, Cyclophosphamide - Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia | Phase 2 | Completed | Northside Hospital, Inc. | 25 | 2015-10-26 | 2023-04-27 |
| Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Rituximab, Conditioning chemotherapy, TMS - Myelodysplastic Syndromes, Hodgkin's Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 34 | 2015-09-24 | 2025-09-30 |
| Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) Pembrolizumab, Etoposide, Ifosfamide - Lymphoma, Hodgkin's Lymphoma | Phase 1 / Phase 2 | Withdrawn | Western Regional Medical Center | 2015-04-01 | 2017-06-27 |
Showing 20 of 101. Sign in to see all of them.
Hodgkin Disease (101) · Lymphoma, Non-Hodgkin (52) · Lymphoma (28) · Multiple Myeloma (25) · Myelodysplastic Syndromes (19) · Leukemia (16) · Leukemia, Myeloid, Acute (16) · Leukemia, Lymphocytic, Chronic, B-Cell (14) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (14) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (9) · Hematologic Neoplasms (8) · Recurrence (8) · Lymphoma, Large B-Cell, Diffuse (7) · Lymphoma, Mantle-Cell (6) · Neoplasms (6)
Hemic and Lymphatic Diseases (101) · Immune System Diseases (101) · Immunoproliferative Disorders (101) · Lymphatic Diseases (101) · Lymphoproliferative Disorders (101) · Neoplasms by Histologic Type (101) · Neoplasms (95) · Lymphoma (73) · Hematologic Diseases (39) · Pathological Conditions, Signs and Symptoms (28) · Pathologic Processes (27) · Blood Protein Disorders (26) · Cardiovascular Diseases (26) · Hemorrhagic Disorders (26) · Hemostatic Disorders (26)
fludarabine (10) · Cyclophosphamide (9) · Filgrastim (8) · Tacrolimus (7) · fludarabine phosphate (7) · Etoposide (6) · Gemcitabine (6) · Melphalan (6) · Mycophenolic Acid (5) · Rituximab (5) · Whole-Body Irradiation (5) · Alemtuzumab (4) · Bendamustine Hydrochloride (4) · Brentuximab Vedotin (4) · Granulocyte Colony-Stimulating Factor (4)
Amgen (4) · Memorial Sloan Kettering Cancer Center (4) · Fondazione Italiana Linfomi - ETS (3) · M.D. Anderson Cancer Center (3) · Massachusetts General Hospital (3) · National Cancer Institute (NCI) (3) · University Health Network, Toronto (3) · Weill Medical College of Cornell University (3) · Armando Santoro, MD (2) · Barbara Ann Karmanos Cancer Institute (2) · Baylor College of Medicine (2) · Dana-Farber Cancer Institute (2) · Italfarmaco (2) · Novartis Pharmaceuticals (2) · Scripps Health (2)
United States (69) · Italy (14) · Canada (9) · France (7) · Poland (6) · Belgium (4) · China (4) · Russia (4) · Germany (3) · Israel (3) · Netherlands (3) · Australia (2) · Brazil (2) · Czechia (2) · Singapore (2)
Armando Santoro, MD (3) · Abhinav Deol, M.D. (2) · Alessandro Massimo Gianni, MD (2) · Dolores Grosso, DNP, CRNP (2) · Neal Flomenberg, MD (2) · Abraham Kanate, MD (1) · Alain Mina, M.D. (1) · Alessandro Levis, MD (1) · Allison Moskowitz, MD (1) · Amer Shammas, Md (1) · Amir A Toor, MD (1) · Anas Younes, M.D. (1) · Anas Younes, MD (1)
PMID 40135712, PMID 22033282, PMID 22080968, PMID 22383790, PMID 22965964, PMID 23990665, PMID 25683846, PMID 25701453, PMID 26009261, PMID 26884559, PMID 27151994, PMID 27354079, PMID 27382096, PMID 28805662, PMID 29351986, PMID 29353109, PMID 29475723, PMID 30658935, PMID 30824040, PMID 31897676, PMID 31935284, PMID 32701411, PMID 32785680, PMID 33586581, PMID 34156881, PMID 34597375, PMID 34990281, PMID 35833116, PMID 37722357, PMID 38669315, PMID 39617826, PMID 40331908
2009 (1), 4UL1TR000427-10 (1), K23AI052413 (1), P01CA049605 (1), P30CA014520 (1), U01HL069294 (1)